We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human||Rat (Rattus)|
|Immunofluorescence (fixed cells) (IF/ICC)||5 Antibodies||4 Antibodies|
|Western Blotting (WB)||105 Antibodies||42 Antibodies|
|Neutralization (Neut)||3 Antibodies|
|Immunoprecipitation (IP)||31 Antibodies||16 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||26 Antibodies||13 Antibodies|
|Immunohistochemistry (IHC)||33 Antibodies||13 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||21 Antibodies|
|Immunohistochemistry (Acetone-fixed) (IHC (af))||1 Antibodies|
|Immunofluorescence (IF)||19 Antibodies||13 Antibodies|
|Immunocytochemistry (ICC)||4 Antibodies|
|Antigen||Tumor Necrosis Factor Receptor Superfamily, Member 1B (TNFRSF1B) Antibodies|
|Epitope||AA 288-318, C-Term Alternatives|
|Reactivity||Human, Rat (Rattus) Alternatives|
|Conjugate||This TNFRSF1B antibody is un-conjugated Alternatives|
Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-TNFRSF1B AntibodyTarget Details TNFRSF1B Application Details Handling Images
|Sequence||KKKPLCLQRE AKVPHLPADK ARGTQGPEQQ H|
|Cross-Reactivity (Details)||No cross reactivity with other proteins.|
Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) detection. Tested with WB in Human,Rat.
Gene Name: tumor necrosis factor receptor superfamily, member 1B
Protein Name: Tumor necrosis factor receptor superfamily member 1B
|Purification||Immunogen affinity purified.|
|Immunogen||A synthetic peptide corresponding to a sequence at the C-terminus of human TNF Receptor II (288-318aa KKKPLCLQREAKVPHLPADKARGTQGPEQQH), different from the related mouse sequence by eleven amino acids, and from the related rat sequence by ten amino acids.|
Target Details TNFRSF1BProduct Details anti-TNFRSF1B Antibody Application Details Handling Images back to top
|Alternative Name||TNFRSF1B (TNFRSF1B Antibody Abstract)|
|Background||Tumor necrosis factor receptor 2 (TNFR2) is one of receptors of TNF. TNF has proinflammatory and immunosuppressive properties that may segregate at the level of the 2 TNF receptors (TNFRs), TNFR1 and TNFR2. The genes for TNFR1, a 55- kDa protein, and TNFR2, a 70- kDa protein, have been mapped to human chromosomes 12 (12pter-cen) and 1 (1pter-p32), respectively. TNFR2 was induced on glomerular endothelial cells of nephritic kidneys, and TNFR2 expression on intrinsic cells, but not leukocytes, was essential for glomerulonephritis and glomerular complement deposition. TNFR1 promotes systemic immune responses and renal T cell death, while intrinsic cell TNFR2 plays a critical role in complement-dependent tissue injury. Therefore, therapeutic blockade specifically of TNFR2 may be a promising strategy in the treatment of immune-mediated glomerulonephritis.|
|Pathways||NF-kappaB Signaling, Apoptosis, Cellular Response to Molecule of Bacterial Origin|
Application DetailsProduct Details anti-TNFRSF1B Antibody Target Details TNFRSF1B Handling Images back to top
WB: Concentration: 0.1-0.5 μg/mL, Tested Species: Human, Rat
Notes: Tested Species: Species with positive results.
Other applications have not been tested. Optimal dilutions should be determined by end users.
Antibody can be supported by chemiluminescence kit ABIN921124 in WB.
|Restrictions||For Research Use only|
HandlingProduct Details anti-TNFRSF1B Antibody Target Details TNFRSF1B Application Details Images back to top
|Reconstitution||Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.|
|Buffer||Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||-20 °C,4 °C|
At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.
ImagesProduct Details anti-TNFRSF1B Antibody Target Details TNFRSF1B Application Details Handling back to top